

## Service description

### 1. Plasmid construction

#### a. Target gene synthesis

When the target gene's nucleotide sequence exhibits high GC content or multiple copies of repetitive sequences, we will communicate and negotiate with the customer in advance, as this situation will increase the difficulty of gene synthesis and sequencing. We cannot guarantee the success of gene synthesis and sequencing. If the customer chooses to proceed with gene synthesis, the related costs and experimental results will be borne by the customer.

#### b. Specific promoter

When constructing viral vectors using specific promoters (predicted from websites or referenced literature, etc.), we cannot guarantee the expression strength and specific targeting of the virus.

### 2. RNAi target sequence screening

a. Exogenous selection (If customers do not have specific requirements, we default to exogenous selection).

- Exogenous selection mainly targets genes from humans, rats, or mice. We do not guarantee the efficiency of exogenous selection when the target gene is from other species.
- Under the condition of ensuring a cell infection efficiency of 90%, we will design and construct three RNAi plasmids targeting the desired gene mRNA. We will consider packaging the virus only when the knockdown efficiency of the target gene at the mRNA level exceeds 60%.
- If the knockdown efficiency of the target gene by the initially designed three RNAi plasmids does not exceed 60% each, we will redesign and construct three new RNAi plasmids for screening free of charge. This will require an additional experimental cycle (this cycle is not counted towards any breach compensation).
- If the knockdown efficiency of the target gene by the redesigned and reconstructed RNAi

plasmids still fails to reach 60%, we undertake to refund 50% of the contract amount to you (this option cannot be combined with other breach compensations); and at the same time, we will provide the overexpression plasmid of the target gene and the RNAi plasmids free of charge to the customer.

- When the different target genes transcription this low homology, prediction software design only 1 set of targets, we will not free for you to do the design targets,
- We don't promise in vivo on virus interference efficiency.

### 3. Virus packaging

- When the target gene is associated with normal physiological functions, knockdown or overexpression may lead to cell death and cessation of growth, thereby preventing virus production in the packaging cells. In such cases, this agreement will terminate automatically. The customer is only required to pay for the completed expenses, including gene synthesis, vector construction, and RNAi target sequence screening and validation.
- If the packaging process involves factors such as excessively large target genes, simultaneous expression of multiple target genes, unconventional serotypes, or membrane glycoproteins, it may result in reduced or failed virus production. In the event that the actual virus yield from packaging is lower than the amount guaranteed in this agreement, the contract will terminate, and the customer is only liable to pay for the completed experimental expenses prior to packaging. Should the customer opt to proceed with further attempts at virus packaging, they will be required to pay a packaging fee of \$500. We will provide the actual virus yield (with an additional packaging cycle, exempt from penalty), and the contract will terminate thereafter.
- When the target gene is a circRNA, due to the uncertainty associated with circRNA splicing, our company does not guarantee the circularization rate or final expression level of circRNA.